Colorectal cancer (CRC) — the second leading cause of cancer death in the United States — is among the most preventable of all malignancies: 90%+ of cases are detectable at highly curable early stages through appropriate screening, and colonoscopic polypectomy can interrupt progression from adenomatous polyp to invasive cancer. Despite decades of public health campaigns and guideline recommendations for screening starting at age 45 (lowered from 50 by the USPSTF and ACS in 2021 to address rising rates in younger adults), approximately 30% of eligible Americans remain unscreened. The expanding menu of screening options — colonoscopy, flexible sigmoidoscopy, fecal immunochemical test (FIT), Cologuard stool DNA test, CT colonography, and now blood-based multicancer detection tests — offers the opportunity to match screening modality to patient preferences and clinical context in ways that may improve overall uptake.
Colonoscopy: Gold Standard with Caveats
Optical colonoscopy remains the reference standard: 10-year surveillance interval in average-risk individuals with normal exam, ability to simultaneously detect and remove polyps, and the best-characterized population-level reduction in CRC mortality (60–70% reduction in long-term studies). The NordICC trial (2022, NEJM) created controversy by showing only 18% relative risk reduction in a per-protocol analysis — but an intention-to-treat colonoscopy invitation group — the more relevant comparison — showed 31% reduction. Critically, NordICC found 79% reduction in CRC-related death among those who actually completed colonoscopy. Colonoscopy's limitations: requires bowel prep (the most common reason for non-completion), sedation, procedure risk (perforation rate 0.5/1,000; bleeding 0.7/1,000), and availability — wait times in many markets exceed 6 months.
Cologuard: Stool DNA Test Performance
Cologuard (Exact Sciences) combines fecal immunochemical testing (FIT) for blood with stool DNA markers (KRAS mutations, aberrant NDRG4 and BMP3 methylation, beta-actin) to detect CRC and advanced precancerous lesions. In the CONFIRM trial validation study (n=10,000): sensitivity for CRC 92.3%, sensitivity for advanced adenoma 42.4%, specificity for CRC absence 86.6%. Every 3-year interval recommended (vs. annual for FIT alone). Cologuard's 14% false positive rate means approximately 1 in 7 people with a positive result do not have cancer or advanced polyps — requiring follow-up colonoscopy to clarify. Medicare covers Cologuard every 3 years for average-risk adults 45–85; most commercial insurers follow. New Cologuard 2.0 (submitted to FDA 2024) shows improved specificity in early trial data.
Blood-Based CRC Tests: The Next Wave
The FDA cleared the first blood-based CRC screening test — Shield (Guardant Health) — in July 2024. Shield detects circulating cell-free DNA methylation patterns associated with CRC with sensitivity of 83% for cancer and 13% for advanced precancerous lesions, and 90% specificity. The USPSTF does not yet include blood-based tests in its 2021 guidelines due to the absence of outcome data. However, the psychological and logistical advantages of a simple blood draw — no bowel prep, no procedure, collection during annual physical — make Shield and pipeline tests from Exact Sciences, Grail, and Biodesix potentially transformative for increasing screening uptake in historically under-screened populations. Healthcare facilities supporting oncology programs should stock laboratory collection supplies for the blood draw protocols required by next-generation CRC screening programs.
